Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Although many anticancer agents for gastric cancer have been developed, the prognosis for many patients remains poor. Recently, costimulatory immune molecules that reactivate antitumor immune responses by utilizing the host immune system have attracted attention as new therapeutic strategies. CD137 is a costimulatory molecule that reportedly potentiates the antitumor activity of tumor-targeting monoclonal antibodies (mAbs) by enhancing antibody-dependent cellular cytotoxicity. However, it remains unclear whether CD137 stimulates tumor-regulatory activity in gastric cancer. In this study, we investigated the antitumor effects of CD137 stimulation on gastric cancer cells administered tumor-targeting mAbs. Our results showed that human natural killer (NK) cells were activated by expressing CD137 after encountering trastuzumab-coated gastric cancer cells, and that stimulation of activated NK cells in the presence of trastuzumab and recombinant human CD137 ligand (rhCD137L) enhanced cytotoxicity and release of cytokines (IFN-γ, TNF, granzyme A, or granzyme B) as compared with activated NK cells with trastuzumab alone (p < 0.05). By combination treatment with rhCD137L, similar effects were obtained regarding cancer cell cytotoxicity in the presence of cetuximab (p < 0.01). Moreover, we revealed that CD137 expression was dependent upon the affinity between the Fc portion of the antibodies and FcγRIIIa of NK cells based on results indicating that human IgG1 and IgG3 subclasses enhanced CD137 expression (p < 0.001). These results confirmed that FcγRIIIA polymorphisms (158 V/V) enhanced CD137 expression to a greater degree than 158 F polymorphisms (p = 0.014). Our results suggested that CD137 stimulation could promote the effects of tumor-targeting mAbs in gastric cancer, and that further investigation of antibody binding affinity and in vivo activities might improve therapeutic strategies related to the treatment of gastric cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig 3 Increased cytokine secretion of trastuzumab-treated NK cells by rhCD137L administration. To investigate NK cell degranulation and cytokine secretion, NK cells were incubated with GLM-4 in the following four conditions: medium alone, trastuzumab (10 ng/mL), rhCD137L (250 ng/mL), or trastuzumab (10 ng/mL) with rhCD137L (250 ng/mL). (A) A representative flow cytometric plot of CD56 and CD107a double staining. Percentage and MFI of CD107a-expressing NK cells from five healthy individuals [p = not significant (NS)]. (B) Cytokine secretion (human IFN-γ, TNF, granzyme A, or granzyme B) determined by the cytometric bead array (*p < 0.005). Data are shown as the mean ± SEM.](https://figures.cochat.ai/paper-figures/d415bb5b473f427787c6d779b68dc697/stimulation-of-natural-killer-cells-with-rhcd137-ligand-enhances-tumor-targeting-figure-3.jpg)
![Fig 4 Enhancement of cetuximab-mediated NK cell cytotoxicity by rhCD137L administration. Purified NK cells were analyzed for cytotoxicity with cetuximab (10 ng/mL) plus rhCD137L (250 ng/mL) in a chromium-release assay, as described previously. NK cells were incubated with gastric cell lines expressing high levels of EGFR [(A) MKN-1 and (B) MKN-45] or low levels of EGFR [(C) TMK-1] under the same conditions. Lysis percentages of the target cells cultured with medium alone (circles), cetuximab (squares), or cetuximab and rhCD137L (triangles) according to chromium release at varying effector (NK cells)/target-cell ratios are shown. (A, B, *p < 0.01; C, p = not significant). Data are shown as the mean ± SEM.](https://figures.cochat.ai/paper-figures/e79a9198fbbd4fda8b4fec23c1e4c633/stimulation-of-natural-killer-cells-with-rhcd137-ligand-enhances-tumor-targeting-figure-4.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This applies to the humanized HER2-specific mAbs trastuzumab and pertuzumab (Misumi et al., 2018; Park et al., 2010; Stagg et al., 2011).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Misumi et al., 2018
In the citing paper
“induction of NK-cell-mediated ADCC of HER2-expressing cancer cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Misumi et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedCD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8429 · Cited by 1,926
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Koizumi, W., Narahara, H., Hara, T., Takagane, A., Akiya, T., Takagi, M., Miyashita, K., Nishizaki, T., Kobayashi, O., Takiyama, W., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70035-4 · Cited by 1,847
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Lordick, F., Kang, Y.-K., Chung, H.-C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70102-5 · Cited by 833
McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.206 · Cited by 820
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Yamane‐Ohnuki, N., Kinoshita, S., Inoue‐Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. (2004) · Biotechnology and Bioengineering · doi:10.1002/bit.20151 · Cited by 572
Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0463 · Cited by 521
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. L., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., Arribas, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 439
Gollob, J., Mier, J. W., Veenstra, K. G., McDermott, D. F., Clancy, D., Clancy, M., & Atkins, M. B. (2000) · PubMed · Cited by 285
Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., & Koenig, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0696 · Cited by 284
Varchetta, S., Gibelli, N., Oliviero, B., Nardini, E., Gennari, R., Gatti, G., Silva, L. S., Villani, L., Tagliabue, E., Ménard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2068 · Cited by 240
Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells
Wilcox, R. A., Chapoval, A. I., Gorski, K. S., Otsuji, M., Shin, T., Flies, D. B., Tamada, K., Mittler, R. S., Tsuchiya, H., Pardoll, D. M., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4262 · Cited by 231
Chemotherapy in gastric cancer: a review and updated meta-analysis
Janunger, K.-G., Hafström, L., & Glimelius, B. (2002) · The European Journal of Surgery · doi:10.1080/11024150201680005 · Cited by 224
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 222
Cell Carriage, Delivery, and Selective Replication of an Oncolytic Virus in Tumor in Patients
Adair, R. A., Roulstone, V., Scott, K. J., Morgan, R., Nuovo, G. J., Fuller, M., Beirne, D., West, E. J., Jennings, V. A., Rose, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003578 · Cited by 192
Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq585 · Cited by 186
Yamashita-Kashima, Y., Iijima, S., Yorozu, K., Furugaki, K., Kurasawa, M., Ohta, M., & Fujimoto-Ouchi, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2927 · Cited by 176
Moehler, M. H., Mueller, A., Trarbach, T., Lordick, F., Seufferlein, T. T. W., Kubicka, S., Geißler, M., Schwarz, S., Galle, P. R., & Kanzler, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq591 · Cited by 128
Lin, W., Voskens, C. J., Zhang, X., Schindler, D. G., Wood, A., Burch, E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 116
Kang, Y.-K., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., Yoshikawa, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.2 · Cited by 107
Combinatorial approach to cancer immunotherapy: strength in numbers
Vilgelm, A. E., Johnson, D. B., & Richmond, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0116-013rr · Cited by 105
Zalevsky, J., Leung, I. W. L., Karki, S., Chu, S. Y., Zhukovsky, E. A., Desjarlais, J. R., Carmichael, D. F., & Lawrence, C. E. (2009) · Blood · doi:10.1182/blood-2008-10-182048 · Cited by 101
Murillo, O., Arina, A., Hervás‐Stubbs, S., Gupta, A., McCluskey, B., Dubrot, J., Palazón, A., Azpilikueta, A., Ochoa, M. C., Alfaro, C., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0285 · Cited by 88
Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W. L., Yoshizawa, H., Yagita, H., Gejyo, F., Okumura, K., & Smyth, M. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903033 · Cited by 82
Matsusaka, S., Nashimoto, A., Nishikawa, K., Miki, A., Miwa, H., Yamaguchi, K., Yoshikawa, T., Ochiai, A., Morita, S., Sano, T., et al. (2015) · Gastric Cancer · doi:10.1007/s10120-015-0518-8 · Cited by 76
Schabowsky, R.-H., Elpek, K. G., Madireddi, S., Sharma, R. K., Yolcu, E. S., Bandura‐Morgan, L., Miller, R. E., MacLeod, K. J., Mittler, R. S., & Shirwan, H. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.127 · Cited by 58
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
Atmaca, A., Werner, D., Pauligk, C., Steinmetz, K., Wirtz, R., Altmannsberger, H., Jäger, E., & Al‐Batran, S. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-524 · Cited by 54
Narazaki, H., Zhu, Y., Luo, L., Zhu, G., & Chen, L. (2010) · Blood · doi:10.1182/blood-2008-12-192591 · Cited by 50
Lim, C. M., Stephenson, R. M., Salazar, A. Μ., & Ferris, R. L. (2013) · OncoImmunology · doi:10.4161/onci.24677 · Cited by 50
Kajitani, K., Tanaka, Y., Arihiro, K., Kataoka, T., & Ohdan, H. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1944-x · Cited by 47
Shimizu, S., Tanaka, Y., Tazawa, H., Verma, S., Onoe, T., Ishiyama, K., Ohira, M., Ide, K., & Ohdan, H. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13492 · Cited by 33
Oboshi, W., Watanabe, T., Matsuyama, Y., Kobara, A., Yukimasa, N., Ueno, I., Aki, K., Tada, T., & Hosoi, E. (2015) · Human Immunology · doi:10.1016/j.humimm.2015.11.001 · Cited by 33
Musolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.51 · Cited by 30
Tabernero, J. M., Hoff, P. M., Shen, L., Ohtsu, A., Yu, R., Eng‐Wong, J., & Kang, Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.tps4150 · Cited by 28
Liu, L., Cao, Y., Tan, A., Liao, C., & Gao, F. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1090-x · Cited by 26
Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy
Makkouk, A., H, V. S. M. P., Chester, C., Chang, S., Colevas, A. D., Sunwoo, J. B., Maecker, H. T., Desai, M., & Kohrt, H. E. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw570 · Cited by 18
Hoff, P. M., Tabernero, J. M., Shen, L., Ohtsu, A., Yu, R., Szado, T., & Kang, Y. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt203.109 · Cited by 13
Chong, K., Ho, W. F., Koo, S. H., Thompson, P., & Lee, E. J. D. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02771.x · Cited by 13
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 67
CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin
Ma, J., Xu, X., Fu, C., Xia, P., Tian, M., Zheng, L., Chen, K., Liu, X., Li, Y., Yu, L., et al. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00312-3 · Cited by 50
Juengpanich, S., Shi, L., Iranmanesh, Y., Chen, J., Cheng, Z., Khoo, A. K.-J., Pan, L., Wang, Y., & Cai, X. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.021 · Cited by 51
“also found that using rhCD137 ligand, which serves as a costimulatory molecule, induces further activation of NK cells, thus increases the efficacy of treatment with tumor-targeting mAbs in gastric cancer patients [136] .”
Metadata
- Authors
- Misumi, T., Tanabe, K., Fujikuni, N., & Ohdan, H.
- Affiliations
- Hiroshima University (JP)
- Corresponding author
- Tanabe, Kazuaki
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-10-15
- Volume
- 13
- Issue
- 10
- Pages
- e0204880
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6188629
- OpenAlex
- W2896438622
- Cited by
- 12
- References
- 52
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Hiroshima University Acedemic Information Repository (Hiroshima University) (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (25462023, 17K10591)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- 4-1BB, natural killer cells, gastric cancer, trastuzumab, cetuximab, antibody-dependent cellular cytotoxicity, FcγRIIIa, FcγRIIIa polymorphism, costimulatory molecules, cytokine production, granzyme A, granzyme B, interferon-gamma, TNF-α
- MeSH terms
- Trastuzumab, Antineoplastic Agents, Immunological, Cell Survival, Drug Synergism, Female, Humans, Killer Cells, Natural, Recombinant Proteins, Stomach Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Cytokines, Cell Line, Tumor, Cell Proliferation, 4-1BB Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.